HARP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HARP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Harpoon Therapeutics's Revenue for the three months ended in Sep. 2023 was $4.45 Mil. Harpoon Therapeutics's average Accounts Receivable for the three months ended in Sep. 2023 was $0.00 Mil.
The historical data trend for Harpoon Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harpoon Therapeutics Annual Data | ||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
Receivables Turnover | Get a 7-Day Free Trial | - | - | - | - | - |
Harpoon Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Receivables Turnover | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Harpoon Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Harpoon Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Harpoon Therapeutics's Receivables Turnover falls into.
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
Harpoon Therapeutics's Receivables Turnover for the fiscal year that ended in Dec. 2022 is calculated as
Receivables Turnover (A: Dec. 2022 ) | |||||||
= | Revenue | / | Average Total Inventories | ||||
= | Revenue (A: Dec. 2022 ) | / ( | (Accounts Receivable (A: Dec. 2021 ) | + | Accounts Receivable (A: Dec. 2022 )) | / | count ) |
= | 31.915 | / ( | (0 | + | 0) | / | 1 ) |
= | 31.915 | / | 0 | ||||
= | N/A |
Harpoon Therapeutics's Receivables Turnover for the quarter that ended in Sep. 2023 is calculated as
Receivables Turnover (Q: Sep. 2023 ) | |||||||
= | Revenue | / | Average Total Inventories | ||||
= | Revenue (Q: Sep. 2023 ) | / ( | (Accounts Receivable (Q: Jun. 2023 ) | + | Accounts Receivable (Q: Sep. 2023 )) | / | count ) |
= | 4.448 | / ( | (0 | + | 0) | / | 1 ) |
= | 4.448 | / | 0 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harpoon Therapeutics (NAS:HARP) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Thank you for viewing the detailed overview of Harpoon Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Vijay K Lathi | 10 percent owner | C/O NEW LEAF VENTURE PARTNERS, 2500 SAND HILL ROAD, SUITE 203, MENLO PARK CA 94025 |
Luke Nathaniel Walker | officer: Chief Medical Officer | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Frank J Lanza | officer: Principal Fin. & Acctng Ofc. | C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Lauren P Silvernail | director | 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618 |
Georgia Erbez | officer: Chief Financial Officer | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Oncology Impact Fund (cayman) Management L.p. | 10 percent owner | 450 KENDALL STREET, CAMBRIDGE MA 02142 |
Mpm Bioventures 2014, L.p. | 10 percent owner | C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142 |
Alan Colowick | director | C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063 |
New Leaf Bpo Associates Ii, L.p. | 10 percent owner | 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170 |
Ronald Hunt | director, 10 percent owner | C/O CREDIT SUISSE 1ST BOSTON PRV EQY, 11 MADISON AVENUE, NEW YORK NY 10010 |
New Leaf Bpo Management Ii, L.l.c | 10 percent owner | 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170 |
New Leaf Ventures Iii, L.p. | 10 percent owner | C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036 |
New Leaf Venture Associates Iii, L.p. | 10 percent owner | C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036 |
New Leaf Venture Management Iii, L.l.c. | 10 percent owner | C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036 |
New Leaf Biopharma Opportunities Ii, L.p. | 10 percent owner | 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170 |
From GuruFocus
By PRNewswire • 01-23-2024
By sperokesalga sperokesalga • 04-17-2023
By sperokesalga sperokesalga • 03-27-2023
By Marketwired • 10-16-2023
By Business Wire • 01-08-2024
By Business Wire • 01-10-2024
By Marketwired • 08-03-2023
By Marketwired • 08-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.